Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Measuring CD8-Positive T-Cells in the Tumor Microenvironment in Classical Hodgkin Lymphoma Using Multiplex Immunofluorescence Staining and Image Analysis: A Possible Prognostic Factor

Hiromichi Takahashi, Shun Ito, Yoko Nakanishi, Katsuhiro Miura, Masaru Nakagawa, Shimon Otake, Takashi Hamada, Takashi Koike, Kazuhide Iizuka, Yuichi Takeuchi, Kazuya Kurihara, Toshihide Endo, Hironao Nukariya, Yoshihiro Hatta, Shinobu Masuda, Hideki Nakamura

Blood (2023) 142 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2023-177853

Published: 2023

Journal Articles

Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study

Masataka Kuwana, Tomoki Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Kensuke Naito, Shingo Kurahashi, Toshiya Kagoo, Kazuki Tanimoto, Natsuko Shichiri, So Saotome, Esteban Masuda, Yoshiaki Tomiyama

Blood (2023) 142 (Supplement 1): 2578.

https://doi.org/10.1182/blood-2023-182113

Published: 2023

Journal Articles

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki, Tohru Murayama, Takeshi Saito, Satoru Takada, Nobuaki Dobashi, Shuichi Ota, Yasuhisa Yokoyama, Masatsugu Tanaka, Shinya Sato, Shigeki Ohtake, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Itaru Matsumura, Yasushi Miyazaki, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2023-178332

Published: 2023

Journal Articles

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Blood (2022) 140 (Supplement 1): 124–126.

https://doi.org/10.1182/blood-2022-156613

Published: 2022

Journal Articles

Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study

Blood (2022) 140 (Supplement 1): 11244–11245.

https://doi.org/10.1182/blood-2022-169782

Published: 2022

Journal Articles

Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study

Blood (2022) 140 (Supplement 1): 6030–6032.

https://doi.org/10.1182/blood-2022-165864

Published: 2022

Journal Articles

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

Blood (2022) 139 (12): 1850–1862.

https://doi.org/10.1182/blood.2021011921

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group

Blood (2021) 138 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2021-149110

Published: 2021

Journal Articles

A Novel Protocol for Rituximab Administration with Reduced Incidence of Severe Infusion-Related Adverse Reactions in Patients with B-Cell Non-Hodgkin Lymphoma

Daisuke Tsutsumi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Shinya Tsuboi, Isamu Odagiri, Takashi Yamauchi, Susumu Ootsuka, Yoshihiro Hatta, Yukinaga Kishikawa

Blood (2021) 138 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2021-145088

Published: 2021

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation Conditioned with Myeloablative Regimens Containing Total Body Irradiation in Adolescent and Young Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Who Were Treated with Pediatric-Type Chemotherapy

Blood (2021) 138 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2021-151855

Published: 2021

Journal Articles

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Blood (2019) 134 (Supplement_1): 743.

https://doi.org/10.1182/blood-2019-123382

Published: 2019

Journal Articles

Von Willebrand Factor (vWF) Levels and Platelet Counts Showed Strong Inverse Correlation in Calreticulin (CALR) Mutated ET, but Weak in JAK2V617F Mutated PV and ET

Kazuhide Iizuka, MD PhD, Noriyoshi Iriyama, MD PhD, Soji Morishita, PhD, Yoshikazu Iizuka, MD PhD, Naotake Yanagisawa, MD PhD, Hamada Takashi, MD PhD, Miharu Watanabe, Masaru Nakagawa, MD PhD, Yoshihito Uchino, MD PhD, Hiromichi Takahashi, MD PhD, Jun Ando, MD PhD, Katsuhiro Miura, MD PhD, Norio Komatsu, MD PhD, Yoshihiro Hatta, MD PhD, Masami Takei, MD PhD

Blood (2018) 132 (Supplement 1): 4313.

https://doi.org/10.1182/blood-2018-99-114013

Published: 2018

Journal Articles

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Noriyoshi Iriyama, MD PhD, Kei-Ji Sugimoto, Eriko Sato, MD PhD, Tomoiku Takaku, MD PhD, Michihide Tokuhira, Tomonori Nakazato, MD PhD, Maho Ishikawa, MD, Hiroyuki Fujita, MD PhD, Yuta Kimura, MD, Isao Fujioka, MD, Norio Asou, MD PhD, Masahiro Kizaki, MD PhD, Norio Komatsu, MD PhD, Yoshihiro Hatta, MD PhD, Tatsuya Kawaguchi, MD PhD

Blood (2018) 132 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2018-99-111732

Published: 2018

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Exerts Dose-Dependent Cytostatic and Cytocidal Effects on Multiple Myeloma Cells Via Autophagy

Noriyoshi Iriyama, MD PhD, Hirotsugu Hino, Shota Moriya, Masaki Hiramoto, Yoshihiro Hatta, MD PhD, Masami Takei, MD PhD

Blood (2016) 128 (22): 4478.

https://doi.org/10.1182/blood.V128.22.4478.4478

Published: 2016

Journal Articles

Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

Koichi Miyamura, MD PhD, Shigeki Ohtake, MD PhD, Kazunori Ohnishi, MD PhD, Noriko Usui, MD PhD, Chiaki Nakaseko, MD PhD, Hiroyuki Fujita, MD PhD, Shin Fujisawa, MD PhD, Toru Sakura, MD, Hirokazu Okumura, Yoshihiro Hatta, MD PhD, Nobuhiko Emi, MD PhD, Tomoki Naoe, MD PhD

Blood (2016) 128 (22): 941.

https://doi.org/10.1182/blood.V128.22.941.941

Published: 2016

Journal Articles

A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2015) 126 (23): 2680.

https://doi.org/10.1182/blood.V126.23.2680.2680

Published: 2015

Journal Articles

Clinical Significance of Co-Expression of MYC and BCL2 Protein in Advanced Diffuse Large B-Cell Lymphoma Treated with a Dose-Intensified Immunochemotherapy

Hiromichi Takahashi, MD PhD, Sumiko Kobayashi, MD PhD, Katsuhiro Miura, MD, Daisuke Kurita, MD, Yoshihiro Hatta, MD PhD, Masahiko Sugitani, MD PhD, Shimon Otake, MD, Masaru Nakagawa, MD PhD, Masashi Sakagami, MD, Yoshihito Uchino, MD, Hitomi Kodaira, MD, Noriyoshi Iriyama, MDPhD, Machiko Kusuda, MD, Atsuko Hojo, Mai Yagi, MD, Yukio Hirabayashi, MD PhD, Yujin Kobayashi, MD PhD, Tomohiro Nakayama, MD PhD, Masami Takei, MD PhD

Blood (2015) 126 (23): 3940.

https://doi.org/10.1182/blood.V126.23.3940.3940

Published: 2015

Journal Articles

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Naoto Takahashi, MD PhD FJSIM, Tetsuzo Tauchi, MDPhD, Kunio Kitamura, MD PhD, Koichi Miyamura, MD PhD, Yoshio Saburi, MD PhD, Yasuhiko Miyata, MD PhD, Yoshihiro Hatta, Fumihiko Kimura, MD, Satoru Takada, MD, Tetsuya Fukuda, MD PhD, Katsumichi Fujimaki, Maho Ishikawa, Itaru Matsumura, MDPhD, Noriko Usui, MD, PhD, Kensuke Usuki, MDPhD, Yukio Kobayashi, MD PhD, Tomoki Naoe, MD PhD

Blood (2015) 126 (23): 4035.

https://doi.org/10.1182/blood.V126.23.4035.4035

Published: 2015

Journal Articles

Imatinib-Based Chemotherapy for Newly Diagnosed BCR–ABL Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study Group (JALSG) Ph+ALL208 Study

Shin Fujisawa, MD, Keitaro Matsuo, MD, PhD, Shuichi Mizuta, MD, Hideki Akiyama, MD, Yasunori Ueda, MD PhD, Yasutaka Aoyama, MD, Yoshihiro Hatta, MD, Kazuhiko Kakihana, MD PhD, Nobuaki Dobashi, MD, Isamu Sugiura, MD PhD, Yasushi Onishi, MD PhD, Tomoya Maeda, MD PhD, Kiyotoshi Imai, MD PhD, Shigeki Ohtake, MD PhD, Yasushi Miyazaki, MD, Kazunori Ohnishi, MD PhD, Tomoki Naoe, MDPhD

Blood (2014) 124 (21): 932.

https://doi.org/10.1182/blood.V124.21.932.932

Published: 2014

NARROW

Measuring CD8-Positive T-Cells in the Tumor Microenvironment in Classical Hodgkin Lymphoma Using Multiplex Immunofluorescence Staining and Image Analysis: A Possible Prognostic Factor

Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study

Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group

A Novel Protocol for Rituximab Administration with Reduced Incidence of Severe Infusion-Related Adverse Reactions in Patients with B-Cell Non-Hodgkin Lymphoma

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Allogeneic Stem Cell Transplantation Conditioned with Myeloablative Regimens Containing Total Body Irradiation in Adolescent and Young Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Who Were Treated with Pediatric-Type Chemotherapy

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Von Willebrand Factor (vWF) Levels and Platelet Counts Showed Strong Inverse Correlation in Calreticulin (CALR) Mutated ET, but Weak in JAK2V617F Mutated PV and ET

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Exerts Dose-Dependent Cytostatic and Cytocidal Effects on Multiple Myeloma Cells Via Autophagy

Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Clinical Significance of Co-Expression of MYC and BCL2 Protein in Advanced Diffuse Large B-Cell Lymphoma Treated with a Dose-Intensified Immunochemotherapy

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Imatinib-Based Chemotherapy for Newly Diagnosed BCR–ABL Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study Group (JALSG) Ph+ALL208 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only